Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
72 hedge funds and large institutions have $21.5M invested in Aralez Pharmaceuticals Inc. in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 25 reducing their positions, and 16 closing their positions.
8% less funds holding
Funds holding: 78 → 72 (-6)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
32% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 25
45% less call options, than puts
Call options by funds: $88K | Put options by funds: $159K
57% less capital invested
Capital invested by funds: $50.2M → $21.5M (-$28.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$367K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$328K |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$289K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$170K |
| 5 |
BlackRock
New York
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Elk Creek Partners
Denver,
Colorado
|
-$5.33M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.56M |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$1.61M |
| 4 |
AC
Armistice Capital
New York
|
-$1.5M |
| 5 |
PP
Prospector Partners
Guilford,
Connecticut
|
-$483K |
ARLZ Hedge Fund Activity: Q2 2017 in Review
72 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q2 2017, worth a combined $21.5M — down 57% from $50.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ARLZ and 11 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 17 added.
The largest buyer was GSA Capital Partners, adding an estimated $367K. The largest seller was Elk Creek Partners, exiting entirely with an estimated $5.33M sold.
- 72 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q2 2017, down from 78 in Q1 2017.
- Funds reported $21.5M of Aralez Pharmaceuticals Inc. stock for Q2 2017, down 57% quarter-over-quarter.
- 11 funds opened new Aralez Pharmaceuticals Inc. positions in Q2 2017 and 16 closed out, a net change of -5 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q2 2017 was GSA Capital Partners, an estimated $367K added.
- The largest Aralez Pharmaceuticals Inc. seller in Q2 2017 was Elk Creek Partners, an estimated $5.33M sold.
Based on aggregated 13F filings for Q2 2017.